Handelsbanken Fonder’s Revance Therapeutics, Inc. RVNC Stock Holding History

Handelsbanken Fonder’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-20,800	Closed	-$102K	–	1597
2024 Q1	$102K	Hold	20,800	–	–	﹤0.01%	1547
2023 Q4	$183K	Buy	20,800 +7,300	+54%	+$59.8K	﹤0.01%	1516
2023 Q3	$155K	Hold	13,500	–	–	﹤0.01%	1509
2023 Q2	$342K	Buy	13,500 +2,200	+19%	+$68.5K	﹤0.01%	1279
2023 Q1	$364K	Hold	11,300	–	–	﹤0.01%	1181
2022 Q4	$209K	Buy	11,300 +1,800	+19%	+$41.2K	﹤0.01%	1419
2022 Q3	$256K	Buy	+9,500	New	+$193K	﹤0.01%	1335
2022 Q1	–	Sell	-16,100	Closed	-$263K	–	1729
2021 Q4	$263K	Hold	16,100	–	–	﹤0.01%	1647
2021 Q3	$449K	Hold	16,100	–	–	﹤0.01%	1423
2021 Q2	$477K	Buy	+16,100	New	+$464K	﹤0.01%	1418

Other funds holding RVNC

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Handelsbanken Fonder's RVNC Position: Q2 2024 in Review

Handelsbanken Fonder sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 20,800 shares — an estimated $102K sold.

Handelsbanken Fonder first reported a position in RVNC in Q2 2021 and held it in 10 quarters. The position peaked at $477K in Q2 2021. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

Handelsbanken Fonder reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
Handelsbanken Fonder sold 20,800 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $102K.
Handelsbanken Fonder first reported a position in Revance Therapeutics, Inc. in Q2 2021 and held it in 10 quarters.
Handelsbanken Fonder's Revance Therapeutics, Inc. position peaked at $477K in Q2 2021.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Handelsbanken Fonder's 13F filing for Q2 2024, filed 5 Aug 2024.